Skip to content


    DEA Class;  Rx

    Common Brand Names; Navane

    • Antipsychotics, 1st Generation
    Antipsychotic drug structurally similar to phenothiazines; 5 mg PO equivalent to 100 mg chlorpromazine; increased risk of death in elderly patients treated for dementia-related psychosis.

    Indicated for the treatment of schizophrenia.

    For the treatment of severe behavioral or psychological symptoms of dementia (BPSD).

    Documented hypersensitivity

    Blood dyscrasias


    Circulatory collapse

    CNS depression (including coma)

    • Constipation
    • Decr sweating
    • Drowsiness
    • EPS ( muscle stiffness, dystonia, Parkinsonism, tardive dyskinesia, akathisia) (60%)
    • Incr appetite
    • Orthostatic hypotension
    • Photosensitivity
    • Wt gain
    • Xerostomia
    • Agitation
    • Allergic dermatitis
    • Allergic reactions
    • Anorexia
    • Anticholinergic effects
    • Anxiety
    • Cerebral edema
    • Depression
    • Dizziness
    • Erectile dysfunction
    • Euphoria
    • Headache
    • Ileus
    • Insomnia
    • Irregular menses
    • Lens opacities (prolonged use)
    • Poikilothermia
    • Rash
    • Restlessness
    • Sedation
    • Tachycardia
    • Weakness
    • Agranulocytosis, blood dyscrasias (rare)
    • Galactorrhea (rare)
    • Heat stroke (rare)
    • NMS (infrequent but serious)
    • Obstructive hyperbilirubinemia (rare)
    • Cholestatic jaundice
    • Confusion
    • Decr gag reflex
    • Gynecomastia
    • Hyperpyrexia
    • Peripheral edema

    Potential cross-sensitivity between thioxanthenes & phenothiazine derivative

    Not for use for dementia in elderly

    Antiemetic effect observed in animal studies; since this effect may also occur in man, it is possible that this drug may mask signs of overdosage of toxic drugs and may obscure conditions such as intestinal obstruction and brain tumor

    Consider known capability of this drug and certain other psychotropic drugs to precipitate convulsions, use extreme caution in patients with history of convulsive disorders or those in a state of alcohol withdrawal; it may lower convulsive threshold; although this drug potentiates the actions of the barbiturates, the dosage of the anticonvulsant therapy should not be reduced when this drug is administered concurrently

    Exhibits rather weak anticholinergic properties; use with caution in patients who might be exposed to extreme heat or who are receiving atropine or related drugs

    Use with caution in patients with cardiovascular disease

    Use caution and adjust dose when used in conjunction with other CNS depressants

    Carefully observe for pigmentary retinopathy and lenticular pigmentation (fine lenticular pigmentation has been noted in a small number of patients treated with this drug for prolonged periods); blood dyscrasias (agranulocytosis, pancytopenia, thrombocytopenic purpura), and liver damage (jaundice, biliary stasis) reported with related drugs

    Safe use during pregnancy not established; drug should be given to pregnant patients only when, in the judgment of the physician, the expected benefits from treatment exceed possible risks to mother and fetus

    Not known if drug excreted in breast milk; other agents preferred in nursing mothers


    60 mg/day PO. Debilitated patients require lower dosages.


    60 mg/day PO. Debilitated patients require lower dosages.


    60 mg/day PO. Debilitated patients require lower dosages.


    12 years: 60 mg/day PO. Debilitated patients require lower dosages.
    1 to 11 years: Safety and efficacy have not been established.


    Safety and efficacy have not been established.



    • 1mg
    • 2mg
    • 5mg
    • 10mg